Keyword: PureTech Ventures
After four years at Neon and a career that’s shown him the many faces of biopharma, Robert Ang is ready to take the plunge and run his own company.
The funding will advance Vor's lead asset, an engineered hematopoietic stem cell therapy for acute myeloid leukemia.
Vedanta Biosciences will advance its pipeline of microbiome-derived drugs, including a handful of assets currently in midstage trials.
The appointment puts the Sage and Voyager co-founder in charge of advancing a muscarinic agonist he worked on at Eli Lilly in the 1990s.
The brain's lymphatic vessels might play a critical role in Alzheimer's and could be a new target for treatment.
The pact gives Roche access to PureTech’s milk-derived exosome technology in return for up to $36 million in near-term payments.
ResTORbio hired Novartis’ Kerry Russell to serve as VP of clinical development as the company aims to expand its pipeline in aging-related diseases.
A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.
The round equips Gelesis to get its manufacturing and commercial arms ready for launch should regulators look favorably on its mixed late-phase data.
Four biotechs spanning a diverse set of therapy targets are seeking out nearly $400 million in a series of IPOs announced just before the New Year.